BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 21098324)

  • 21. Medulloblastoma subgroups remain stable across primary and metastatic compartments.
    Wang X; Dubuc AM; Ramaswamy V; Mack S; Gendoo DM; Remke M; Wu X; Garzia L; Luu B; Cavalli F; Peacock J; López B; Skowron P; Zagzag D; Lyden D; Hoffman C; Cho YJ; Eberhart C; MacDonald T; Li XN; Van Meter T; Northcott PA; Haibe-Kains B; Hawkins C; Rutka JT; Bouffet E; Pfister SM; Korshunov A; Taylor MD
    Acta Neuropathol; 2015 Mar; 129(3):449-57. PubMed ID: 25689980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
    Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
    J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
    Korshunov A; Remke M; Werft W; Benner A; Ryzhova M; Witt H; Sturm D; Wittmann A; Schöttler A; Felsberg J; Reifenberger G; Rutkowski S; Scheurlen W; Kulozik AE; von Deimling A; Lichter P; Pfister SM
    J Clin Oncol; 2010 Jun; 28(18):3054-60. PubMed ID: 20479417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles.
    Korshunov A; Sahm F; Okonechnikov K; Ryzhova M; Stichel D; Schrimpf D; Casalini B; Sievers P; Meyer J; Zheludkova O; Golanov A; Lichter P; Jones DTW; Pfister SM; Kool M; von Deimling A
    Acta Neuropathol; 2019 Jun; 137(6):1003-1015. PubMed ID: 30826918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A mouse model of the most aggressive subgroup of human medulloblastoma.
    Kawauchi D; Robinson G; Uziel T; Gibson P; Rehg J; Gao C; Finkelstein D; Qu C; Pounds S; Ellison DW; Gilbertson RJ; Roussel MF
    Cancer Cell; 2012 Feb; 21(2):168-80. PubMed ID: 22340591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization.
    Tong CY; Hui AB; Yin XL; Pang JC; Zhu XL; Poon WS; Ng HK
    J Neurosurg; 2004 Feb; 100(2 Suppl Pediatrics):187-93. PubMed ID: 14758948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors.
    von Hoff K; Hartmann W; von Bueren AO; Gerber NU; Grotzer MA; Pietsch T; Rutkowski S
    Pediatr Blood Cancer; 2010 Mar; 54(3):369-76. PubMed ID: 19908297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features.
    Tamayo P; Cho YJ; Tsherniak A; Greulich H; Ambrogio L; Schouten-van Meeteren N; Zhou T; Buxton A; Kool M; Meyerson M; Pomeroy SL; Mesirov JP
    J Clin Oncol; 2011 Apr; 29(11):1415-23. PubMed ID: 21357789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.
    Milde T; Lodrini M; Savelyeva L; Korshunov A; Kool M; Brueckner LM; Antunes AS; Oehme I; Pekrun A; Pfister SM; Kulozik AE; Witt O; Deubzer HE
    J Neurooncol; 2012 Dec; 110(3):335-48. PubMed ID: 23054560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytogenetic prognostication within medulloblastoma subgroups.
    Shih DJ; Northcott PA; Remke M; Korshunov A; Ramaswamy V; Kool M; Luu B; Yao Y; Wang X; Dubuc AM; Garzia L; Peacock J; Mack SC; Wu X; Rolider A; Morrissy AS; Cavalli FM; Jones DT; Zitterbart K; Faria CC; Schüller U; Kren L; Kumabe T; Tominaga T; Shin Ra Y; Garami M; Hauser P; Chan JA; Robinson S; Bognár L; Klekner A; Saad AG; Liau LM; Albrecht S; Fontebasso A; Cinalli G; De Antonellis P; Zollo M; Cooper MK; Thompson RC; Bailey S; Lindsey JC; Di Rocco C; Massimi L; Michiels EM; Scherer SW; Phillips JJ; Gupta N; Fan X; Muraszko KM; Vibhakar R; Eberhart CG; Fouladi M; Lach B; Jung S; Wechsler-Reya RJ; Fèvre-Montange M; Jouvet A; Jabado N; Pollack IF; Weiss WA; Lee JY; Cho BK; Kim SK; Wang KC; Leonard JR; Rubin JB; de Torres C; Lavarino C; Mora J; Cho YJ; Tabori U; Olson JM; Gajjar A; Packer RJ; Rutkowski S; Pomeroy SL; French PJ; Kloosterhof NK; Kros JM; Van Meir EG; Clifford SC; Bourdeaut F; Delattre O; Doz FF; Hawkins CE; Malkin D; Grajkowska WA; Perek-Polnik M; Bouffet E; Rutka JT; Pfister SM; Taylor MD
    J Clin Oncol; 2014 Mar; 32(9):886-96. PubMed ID: 24493713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics of medulloblastoma in children under age of three years.
    Ryzhova MV; Zheludkova OG; Kumirova ÉV; Shishkina LV; Panina TN; Gorelyshev SK; Khukhlaeva EA; Mazerkina NA; Matuev KB; Medvedeva OA; Tarasova EM; Kholodov BV; Kapitul'skaia OIu
    Zh Vopr Neirokhir Im N N Burdenko; 2013; 77(1):3-10; discussion 11. PubMed ID: 23659115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Active medulloblastoma enhancers reveal subgroup-specific cellular origins.
    Lin CY; Erkek S; Tong Y; Yin L; Federation AJ; Zapatka M; Haldipur P; Kawauchi D; Risch T; Warnatz HJ; Worst BC; Ju B; Orr BA; Zeid R; Polaski DR; Segura-Wang M; Waszak SM; Jones DT; Kool M; Hovestadt V; Buchhalter I; Sieber L; Johann P; Chavez L; Gröschel S; Ryzhova M; Korshunov A; Chen W; Chizhikov VV; Millen KJ; Amstislavskiy V; Lehrach H; Yaspo ML; Eils R; Lichter P; Korbel JO; Pfister SM; Bradner JE; Northcott PA
    Nature; 2016 Feb; 530(7588):57-62. PubMed ID: 26814967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma.
    Leal LF; Evangelista AF; de Paula FE; Caravina Almeida G; Carloni AC; Saggioro F; Stavale JN; Malheiros SMF; Mançano B; de Oliveira MA; Luu B; Neder L; Taylor MD; Reis RM
    Neuropathology; 2018 Oct; 38(5):475-483. PubMed ID: 30155928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas.
    Eberhart CG; Kratz JE; Schuster A; Goldthwaite P; Cohen KJ; Perlman EJ; Burger PC
    Brain Pathol; 2002 Jan; 12(1):36-44. PubMed ID: 11770900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma.
    Grotzer MA; Hogarty MD; Janss AJ; Liu X; Zhao H; Eggert A; Sutton LN; Rorke LB; Brodeur GM; Phillips PC
    Clin Cancer Res; 2001 Aug; 7(8):2425-33. PubMed ID: 11489822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
    Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
    J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological characteristics, molecular subgrouping, and expression of miR-379/miR-656 cluster (C14MC) in adult medulloblastomas.
    Kaur K; Kakkar A; Kumar A; Purkait S; Mallick S; Suri V; Sharma MC; Julka PK; Gupta D; Suri A; Sarkar C
    J Neurooncol; 2016 Dec; 130(3):423-430. PubMed ID: 27576698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behavior.
    McManamy CS; Pears J; Weston CL; Hanzely Z; Ironside JW; Taylor RE; Grundy RG; Clifford SC; Ellison DW;
    Brain Pathol; 2007 Apr; 17(2):151-64. PubMed ID: 17388946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes.
    Sharma T; Schwalbe EC; Williamson D; Sill M; Hovestadt V; Mynarek M; Rutkowski S; Robinson GW; Gajjar A; Cavalli F; Ramaswamy V; Taylor MD; Lindsey JC; Hill RM; Jäger N; Korshunov A; Hicks D; Bailey S; Kool M; Chavez L; Northcott PA; Pfister SM; Clifford SC
    Acta Neuropathol; 2019 Aug; 138(2):309-326. PubMed ID: 31076851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined genome-wide allelotyping and copy number analysis identify frequent genetic losses without copy number reduction in medulloblastoma.
    Langdon JA; Lamont JM; Scott DK; Dyer S; Prebble E; Bown N; Grundy RG; Ellison DW; Clifford SC
    Genes Chromosomes Cancer; 2006 Jan; 45(1):47-60. PubMed ID: 16149064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.